Immune checkpoint inhibitor administration during pregnancy: a case series

Area of Science:

• Oncology
• Immunology
• Maternal-Fetal Medicine

Background:

• Immune checkpoint inhibitors (ICIs) are standard cancer treatments.
• Cancer in pregnancy is rare but poses treatment challenges.
• Limited data exist on ICI use during pregnancy.

Purpose of the Study:

• To review and synthesize available data on immunotherapy in pregnant women.
• To evaluate the efficacy and safety of immunotherapy during pregnancy.

Main Methods:

• Systematic review of studies from January 2000 to April 2021.
• Searched PubMed and FDA Adverse Events Reporting System.
• Included studies on 'immunotherapy', 'cancer', and 'pregnancy'.

Main Results:

• Seven articles (seven pregnancies, nine neonates) were analyzed.
• Melanoma was the only reported malignancy.
• 71.4% of pregnancies had complications, including intrauterine growth restriction and prematurity.

Conclusions:

• ICI administration during pregnancy is linked to increased pregnancy complications.
• Preterm birth and low birth weight are significant risks.
• ICIs are not recommended during gestation; close monitoring is essential if used.